I Took Kisunla Despite the Dangers - Here's Why

One year ago, I made a significant decision to become a test pilot for a new Alzheimer's disease drug, Kisunla. Despite knowing the risks of this medicine, including brain swelling and bleeding, my initial diagnostic PET scan results motivated me to proceed. This experience highlights the ongoing challenges of dementia and the importance of early diagnosis for patients seeking treatment. 0:00 – Why I chose Kisunla (and what I was afraid of) 1:38 – The reality of 12 infusion visits 2:25 – Side effect risks (ARIA) explained from a patient’s view 4:22 – Reading my PET scan report (the moment I’ll never forget) 5:50 – What “no amyloid plaque” actually means 7:06 – Do I need maintenance infusions? What my doctors say 7:22 – A road map for the future 8:16 – Was it worth it? 8:48 -- Today - I'm winning the battle If you or a loved one is considering Kisunla, I hope this gives you the patient perspective I wish I had a year ago.